Medpace (NASDAQ:MEDP) Releases Quarterly Earnings Results, Beats Estimates By $0.54 EPS

Medpace (NASDAQ:MEDP) issued its quarterly earnings results on Wednesday. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54, FiscalAI reports. The company had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%. Medpace updated its FY 2026 guidance to 16.680-17.500 EPS.

Medpace Stock Performance

Shares of Medpace stock traded down $6.44 during trading on Wednesday, reaching $508.46. The company had a trading volume of 398,616 shares, compared to its average volume of 342,794. The company has a market cap of $14.52 billion, a price-to-earnings ratio of 33.23, a price-to-earnings-growth ratio of 2.49 and a beta of 1.39. The firm’s fifty day moving average is $469.72 and its 200-day moving average is $537.76. Medpace has a fifty-two week low of $282.84 and a fifty-two week high of $628.92.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Zacks highlights Medpace’s growth attributes — strong revenue and earnings growth, high ROE, and long-term pipeline potential — arguing MEDP remains a solid growth stock that could deliver exceptional returns if execution continues. Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think “Yes”
• Neutral Sentiment: Cincinnati plans a bike path near Medpace’s Madisonville headquarters — a local infrastructure project with limited direct financial impact but positive for community relations and employee access. Cincinnati to build bike path near headquarters of one of region’s largest companies
• Neutral Sentiment: Market previews and analyst notes ahead of Medpace’s Q1 report could drive volatility around the print; investors should watch guidance commentary vs. expectations. Medpace (MEDP) Q1 Earnings: What To Expect
• Negative Sentiment: Multiple law firms have filed claims or are soliciting lead plaintiffs in a securities class action alleging Medpace overstated growth projections and harmed investors (class period: April 22, 2025 — February 9, 2026). Firms are urging investors to seek lead‑plaintiff status before a June 8, 2026 deadline — the surge of notices increases legal overhang and headline risk that likely pressured the stock. Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit

Analyst Upgrades and Downgrades

Several brokerages have weighed in on MEDP. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a report on Friday, February 13th. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Barclays raised shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price objective for the company in a research report on Friday, March 6th. Leerink Partners decreased their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. Finally, Mizuho set a $582.00 target price on shares of Medpace in a research note on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $486.67.

Insider Activity

In related news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Medpace

Institutional investors and hedge funds have recently bought and sold shares of the business. Sivia Capital Partners LLC acquired a new stake in Medpace during the second quarter worth about $296,000. Abel Hall LLC acquired a new stake in Medpace during the fourth quarter worth about $202,000. Tower Research Capital LLC TRC raised its stake in Medpace by 41.4% during the second quarter. Tower Research Capital LLC TRC now owns 533 shares of the company’s stock worth $167,000 after acquiring an additional 156 shares during the period. iSAM Funds UK Ltd acquired a new stake in Medpace during the third quarter worth about $149,000. Finally, State of Wyoming raised its stake in Medpace by 42.3% during the fourth quarter. State of Wyoming now owns 222 shares of the company’s stock worth $125,000 after acquiring an additional 66 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.